Johnson & Johnson (JNJ)
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
Johnson & Johnson JNJ, the iconic healthcare giant known for its stable dividends and defensive appeal, has entered a bearish technical pattern: the Death Cross.
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
US FDA proposes standardized testing to detect asbestos in talc products
The U.S. Food and Drug Administration is proposing that cosmetic products containing talc should be tested using standardized methods to detect asbestos, a potential contaminant, according to documents posted on the federal register on Thursday.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks
Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses.
Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note
In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Johnson & Johnson: Dividend Legend At A Discount
Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage, ample liquidity, and impressive free cash flow margin support its dividend sustainability and long-term growth. The stock is very attractively valued with an 18% potential upside.
Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego.
